Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunome, Inc. - Common Stock (NQ:IMNM)

16.88 +1.19 (+7.58%)
Streaming Delayed Price Updated: 2:26 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Immunome Announces Pricing of Upsized Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Analyst Expectations For Immunome's Future
 
Via Benzinga
Evaluating Immunome: Insights From 4 Financial Analysts
 
Via Benzinga
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
From Hummingbird Bioscience
Via GlobeNewswire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
3 Small-Cap Stocks With Big Growth Potential
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space. 
Via MarketBeat
Topics Economy
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From Immunome, Inc.
Via Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Stock Sees RS Rating Jump To 91
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
From Immunome, Inc.
Via Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.